Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7960425 | 0.93 | ALDH1A1 (0.40) | CCKBRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6177683 | 0.91 | CCKBR (0.36) | CCKBRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7960830 | 0.85 | CCKBR (0.35) | CCKBRSCN9ALMNATSHR | |
| SCHEMBL6177954 | 0.85 | TP53 (0.38) | CCKBRALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6176603 | 0.85 | CCKBR (0.39) | CCKBRSCN9ALMNATSHRMAPT | |
| SCHEMBL6181983 | 0.84 | CCKBR (0.36) | CCKBRALDH1A1SCN9ALMNATP53 | |
| SCHEMBL6178413 | 0.83 | ALDH1A1 (0.40) | ALDH1A1CYP1A2CYP2D6CYP2C19LMNA | |
| SCHEMBL7959681 | 0.83 | CCKBR (0.35) | CCKBRSCN9A | |
| SCHEMBL6176746 | 0.82 | CCKBR (0.52) | CCKBR | |
| SCHEMBL6177998 | 0.82 | CCKBR (0.47) | CCKBRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |